4613-C CLINICAL, GENETIC, AND PATHOLOGIC FEATURES, TREATMENT, AND LONG-TERM OUTCOME IN PATIENTS WITH BENIGN RECURRENT INTRAHEPATIC CHOLESTASIS: A MULTICENTER STUDY IN JAPAN Ken Kato 1 , Shuichiro Umetsu 2 , Takao Togawa 3 , Koichi Ito 3 , Takayoshi Kawabata 4 , Teruko Arinaga-Hino 1 , Naoya Tsumura 1 , Ryosuke Yasuda 1 , Yutaro Mihara 1 , Hironori Kusano 1 , Shogo Ito 3 , Kazuo Imagawa 5 , Hisamitsu Hayashi 6 , Ayano Inui 2 , Yushiro Yamashita 1 and Tatsuki Mizuochi 1 , (1)Kurume University School of Medicine, (2)Saiseikai Yokohamashi Tobu Hospital, (3)Nagoya City University Graduate School of Medical Sciences, (4)Ishikawa Prefectural Central Hospital, (5)University of Tsukuba, (6)The University of Tokyo Background: There have been few reports of benign recurrent intrahepatic cholestasis (BRIC) from East Asia
Efficient mitochondrial glutamine targeting prevails over glioblastoma metabolic plasticity
Although current therapies have improved clinical outcomes, they primarily offer symptomatic relief, underscoring the need for novel disease-modifying strategies
HCG can be used alongside TRT for a variety of reasons, such as: ( 4 ) Preserving fertility by maintaining sperm production Preventing testicular shrinkage Supporting natural testosterone production in conjunction with TRT For men who want the benefits of TRT without sacrificing long-term reproductive health, HCG is an important part of the equation
